Related Experiment Videos

High cost patients and the consortium approach

Susan Schonfield1, Keith Reid

  • 1Merton, Sutton & Wandsworth Health Authority, Mitcham, UK. susan.schonfield@mswha.sthames.nhs.uk

Insights

The Pan-Thames Haemophilia Consortium improved regional planning for haemophilia services. High-cost therapies for a small patient group consumed a significant portion of the treatment budget.

Area of Science:

  • Healthcare Management
  • Public Health
  • Hematology

Background:

  • The establishment of the Pan-Thames Haemophilia Consortium aimed to centralize and optimize regional haemophilia service planning.
  • An Expert Advisory Group was formed to address high-cost elective treatment programs within the consortium.

Purpose of the Study:

  • To evaluate the initial year of the Pan-Thames Haemophilia Consortium's activities.
  • To analyze the resource allocation for high-cost therapies within the consortium's budget.

Main Methods:

  • An audit was conducted on the consortium's first year of operational data.
  • Patient demographics and treatment expenditure were analyzed.

Main Results:

  • Patients receiving high-cost therapy constituted 1.6% of the total patient population.
  • These patients accounted for 16% of the overall treatment budget.

Conclusions:

  • The consortium demonstrated focused commissioning expertise in managing specialized haemophilia services.
  • The Pan-Thames model offers a framework for national commissioning strategies for haemophilia care.

Related Concept Videos